A discussion pertaining to the significance of biomarker testing and precision medicine in non–small cell lung cancer.
EP. 1: Novel-Based Treatment Approaches in NSCLC
Advances in non-small cell lung cancer that have helped lung oncologists make more informed treatment decisions with patients.
EP. 2: Overcoming Barriers to Lung Cancer Screening
Challenges surrounding the screening of high-risk patients for lung cancer in the community.
EP. 3: Education on NSCLC Symptoms and Risk Factors
Approaches that can help lung oncologists discuss symptoms and risk factors of non-small cell lung cancer with patients and their loved ones.
EP. 4: Predictive and Prognostic Biomarkers in NSCLC
Drs. Charu Aggarwal and Hossein Borghaei comment on the importance of having predictive and prognostic biomarkers in non-small cell lung cancer and highlight their approaches to testing patients prior to initiating therapy.
EP. 5: Addressing Barriers to Molecular Testing in NSCLC
Reactions to low rates of molecular testing for patients with non-small cell lung cancer in community settings.
EP. 6: Counseling Patients With NSCLC About Molecular Testing
What patients need to know about molecular testing and treatment decisions in non-small cell lung cancer.
EP. 7: Tissue and Liquid Biopsies in NSCLC
The difference between tissue and liquid biopsies used in non-small cell lung cancer, and what patients should know about their results and treatment decision-making.
EP. 8: Individualized Treatment Decisions for Patients With NSCLC
The rationale for waiting on results of molecular testing prior to initiating treatment for patients with non-small cell lung cancer.
EP. 9: PD-L1 Testing in NSCLC
The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer.
EP. 10: Repeat Biopsies as NSCLC Progresses
Preferences for repeat biopsies upon progression in non-small cell lung cancer following frontline therapy with a targeted treatment approach.
EP. 11: Immunotherapy for Patients With NSCLC
Considerations for treating patients with non-small cell lung cancer with single-agent immunotherapy vs chemoimmunotherapy.
EP. 12: Shared Decision-Making in NSCLC
The significance of shared decision-making between patients and lung oncologists when considering a novel-based therapy as treatment for non-small cell lung cancer.
EP. 13: NSCLC: Preparing Patients for Treatment-Related Side Effects
Strategies that can help various health care professionals best mitigate or manage side effects associated with newer treatments in non-small cell lung cancer, such as immunotherapy.
EP. 14: Rechallenging Therapy in NSCLC
Preferences for rechallenging patients with non-small cell lung cancer with immunotherapy based on previous experiences in terms of treatment-related side effects.
EP. 15: Adopting Precision Medicine in NSCLC
Take-home messages from a discussion on the use of biomarker testing, and newer, novel-based strategies to treat patients with non-small cell lung cancer.
2 Commerce Drive Cranbury, NJ 08512